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ABSTRACT  the discovery of the pharmaceutical potential of small molecule inhibitors of oncogenic protein tyrosine kinases is one of the directions in target therapy 
in oncology. Presently, investigations aiming at developing new therapeutically important inhibitors have to be based on a combination of computational and 
experimental approaches including biochemical, cell-based or in silico screening and the study of the three-dimensional structure of the kinase active center, in 
complex with an inhibitor, using crystallography and X-ray analysis or molecular modeling. this work is an example of a combination of inhibitor experimental 
search with the computational analysis of the potential mechanism of the inhibitors’ action, which allowed to propose the 2-hydroxyphenol group as a scaffold 
for the design of new tyrosine kinase inhibitors. 
Keywords: protein tyrosine kinases; small molecule inhibitors; screening; 2-hydroxyphenol group.
INTRODuCTION
the discovery of the role of oncogenic protein tyrosine kinas-
es (PtKs) capable of noncontrolled activation in the develop-
ment of cancer due to genetic alterations and the therapeutic 
potential of their inhibition has led to the emergence of a new 
era in oncology characterized by the appearance of selective 
(targeted to the specific protein) drugs in clinical practice [1]. 
Application of the small molecule inhibitors that prevent the 
binding of AtP to the catalytic domains of PtKs, thus in-
terfering with the activities of the kinases, was considered 
as the most promising strategy in the inhibition of oncogenic 
PtKs [2]. the first AtP-competitive drug successfully used 
in human therapy was imatinib (gleevec), which acts against 
the Kit and PDGF receptors and inhibits nonreceptor fusion 
kinase Bcr-Abl [3].  recently, a number of inhibitors have 
been approved for clinical use and more of them are at dif-
ferent stages of evaluation. However, the search for novel 
classes of chemical compounds acting against PtKs continues 
[4]. the ever-increasing degree of activity shown by scientists 
in the field of protein kinase inhibitor development could be 
attributed to the mentioned role of the majority of PtKs in 
oncogenesis [2], as well as the phenomena of resistance by 
some mutant PtKs to known inhibitors [5]. Furthermore, the 
problem of the low selectivity of AtP-competitive small mol-
ecule inhibitors [6] and, on the other hand, the therapeutic 
advantage of parallel inactivation of several oncogenic key 
points [7] deserve notice.  
Modern research aiming at developing new therapeuti-
cally important inhibitors has to be based on a combination of 
computational and experimental approaches including bio-
chemical, cell-based, or in silico screening and the study of 
the three-dimensional structure of the kinase active center, 
in complex with an inhibitor, using crystallography and X-
ray analysis or molecular modeling [8, 9]. Obviously, computa-
tional methods require information on the three-dimensional 
structure of the active center of a target protein or its homo-
logues, even as all modeling predictions have to be validated 
experimentally.  thus, the search for novel active compounds 
and the assessment of the known inhibitor’s molecular spe-
cificity require the generation of various recombinant PtK 
panels [6]. the conventional approach to obtaining function-
ally active PtKs is the baculoviral expression system [10].
the aim of the present study was to generate a panel of 
functionally active protein tyrosine kinases and to search for 
their inhibitors in a small-molecule collection. Analysis of the 
screening results using molecular modeling allowed to pro-
pose the 2-hydroxyphenol group as a potential scaffold for 
the design of novel tyrosine kinase inhibitors.
MATERIALS AND METHODS
MATERIALS
to obtain functionally active protein tyrosine kinases, bacu-
lovirus expression system «Bac-to-Bac» (Invitrogen, uSA) 
was used. 
For the search for the protein tyrosine kinase inhibitor, a 
collection of small organic molecules containing more than 
ten thousand individual compounds with molecular weights 
ranging from 150 to 600 was provided by chembridge corp. 
Moscow (http://chembridge.com/datasheets/KInASet.pdf). 
All compounds were dissolved in DMSO to a concentration of 
1 mM, and the aliquots were stored at -20°c.
METHODS
Generation of baculoviruses.  cDnAs corresponding to the 16 
PtKs were cloned into the t-easy vector (Promega, uSA) us-
ing the conventional approach of reverse transcription – Pcr 
with the total rnA as a template. the full list of the PtKs and 
the summary of cloning are presented in table 1. Once the 
cloned inserts were verified by sequencing, cDnA fragments 
were recloned into the vector pFastBacHt-B downstream 
of and in frame with 6xHis-tag. the obtained plasmids were reSeArcH ArtIcLeS
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used to transform E. coli cells DH10Bac (Invitrogen, uSA), 
wherein the recombination of the target genes with the bacu-
loviral genome occurred. recombinant bacmides isolated from 
E. coli were introduced into insect cells Spodoptera frugiper-
da (Sf9) plated on 6-well plates and cultivated at 27°c. Virus 
particles assembled in the transfected cells and then induced 
cell lysis and accumulated in the growth media. Infected in-
sect cells were expressing and accumulating recombinant tar-
get 6xHis-PtKs.  All manipulations with baculoviruses were 
conducted according the manufacturer’s instructions for the 
expression system Bac-to-Bac (Invitrogen,uSA).
Purification of 6xHis-PTKs.  cell pellets (~109 cells or  10 g of 
a biomass) from 1 L of the infected cell culture were frozen   
at -70°c and then lyzed in 50 ml of buffer A (20 mM tris-Hcl 
pH 8.5, 500 mM nacl, and 0.1 % triton X-100)  supplemented 
with 10 u of rQ1 DnAase and a protease inhibitor cocktail.   
the lysate was cleared by centrifugation (15,000 g, 1 h, +4°c) 
and incubated with 2 ml of ni2+-sepharose at +4°c for an 
hour. After the binding, the resin was washed with buffer A 
containing 30 mM imidasol until the protein detected in the 
wash fractions was absent. then the 6xHis-PtK was eluted 
with buffer A containing 350 mM imidasol. For the exchange 
of the elution buffer to the storage buffer (50 mM tris-Hcl 
pH 8.5, 100 mM nacl, and 0.05 % triton X-100), PD10 col-
umns were used according to the manufacturer’s recom-
mendations. All isolated proteins were stored at -20 °c in 50% 
glycerol and 2 mM Dtt.
Measurement of 6xHis-PTK activities. the reaction mix-
ture for each kinase assay contained 10 μM AtP, 10 μg of 
universal protein tyrosine kinase substrate poly(Glu4-tyr) 
(Sigma, uSA), and one of the sixteen PtKs in amounts of 30, 
60 or 90 ng in the 1xkinase buffer (50 mM tris-Hcl, pH 7.5, 
5 mM Mncl2, 5 mM Mgcl2, 0.01% tween-20, and 2 mM Dtt). 
to control the starting AtP level, a reaction mixture lack-
ing kinase was prepared and introduced in each set of assays. 
Kinase assays were performed in a total volume of 30 μL, in 
Table 1.  Summary of the PTK panel generation 
Protein tyrosine Kinase (PtK) Acc. no
AA Direct & reverse primers1 (5’-3’)
Abl - Abelson Murine Leukemia Viral Oncogene Homolog 1 NP_005148 2-601 GGATCCttGGAGAtctGcctGAAGctG
ACTCGAGccGAAcAAGttGGtcttttG
Alk - Anaplastic Lymphoma Kinase receptor NP_004295 1092-1406 cAtGGATCCctAcAAccccAActAc
GCTCGAGttAttccAcAAGtGGAccAt
Blk - B-Lymphocyte Kinase NP_001706 2-505 GGATCCGGGctGGtAAGtAGcA
CTCGAGGGctGcAGctcGtActG
cSF1r - colony Stimulating Factor 1 receptor NP_005202 545-972 GGATCCAAGtAccAGGtccGct
CTCGAGcAGAActGAtAGttGttG
csk - c-terminal c-Src Kinase NP_004374 2-450 tGGATCCtcAGcAAtAcAGGccGcc
ACTCGAGAGGtGcAGctcGtGGGtt
eph A2 - ephrin receptor A2 NP_004422 562-976 AGATCTAGGAGGAAGAAccAGc
CTCGAGAtGGGGAtccccAcAG
FGFr1 - Fibroblast Growth Factor receptor 1 NP_056934 398-820 GGATCCAAGAGtGGtAccAAGAAGAGt
ttCTCGAGcGGcGtttGAGtccGccAtt
FGFr2 - Fibroblast Growth Factor receptor 2 NP_075259 402-822 GGATCCAAGAAcAcGAccAAGAAGc
CTCGAGGttttAAcActGccGtttAtG
IGFr1 - Insulin-like Growth Factor 1 receptor  NP_000866 974-1294 GGATCCAGAAAGAGAAAtAAcAGcAGG
GCTCGAGttAAtccAGctcctccGGctc
Insr - Insulin receptor NP_000199 982-1382 GGATCCAGGcAGccAGAtGGGccGctG
CTCGAGGAAGGAttGGAccGAGGcAAG
Kit - Stem cell Factor receptor NP_000213 545-976 tGGATCCtAcAAAtAtttAcAGAAAccc
ttCTCGAGAcAtcGtcGtGcAcAAGcAG
Lyn - Yamaguchi Sarcoma Viral related Oncogene Homolog 2 NP_002341 full length GGGATCCGGAtGtAtAAAAtcAAAAGG
GGAAttCTCGAGGGctGctGctGGtAtt
PDGFra - Platelet-Derived Growth Factor receptor-a NP_006197 552-1089 GGATCCAAGccAcGttAcGAGAtccGAt
GTCGACAGGAAGctAtcctctGcttccG
Pyk2 - Focal Adhesion Kinase 2  NP_004094 353-762 tGGATCCcGGctGcAGGGtGAGcAccA 
ttCTCGAGttAAcGGGAGAtGGAtActc 
Syk - Spleen tyrosine Kinase NP_003168 full length GGATCCGccAGcAGcGGcAtGGctGAc
CTCGAGttcAccAcGtcAtAGtAGtA
Yes – Yamaguchi Sarcoma Viral Oncogene Homolog 1 NP_005424 11-542 cGGGATCCccAGccAttAAAtAcAGAc
tcGTCGACAAAttttctcctGGctGGtA
1 – sites used for subcloning from T-easy vector into pFastBacHT-B are in bold.86 | ActA nAturAe |  № 3 2009
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384-well plates at 30°c for 15 min and developed with 10 μL 
of the Kinase-Glo reagent. the luminescence was detected 
using the Fusion universal Microplate Analyzer (Perkinelmer 
uSA). the activities of the recombinant PtKs were assessed 
in two independent experiments performed in triplicates.
Screening of the small-molecule collections.  the screening 
was performed by assessment of the chemical compound’s 
potential to inhibit tyrosine kinase activities using the lumi-
nescent kinase assay. All kinase reaction components were 
freshly diluted in the 1xkinase buffer. Assays were performed 
in 384 well microplates manually or using MultiPrOBe II 
(Packard, uSA). control samples containing AtP and kinase 
with DMSO instead of the inhibitors (0% inhibition) and AtP 
without kinase (100% inhibition) were included in each assay 
plate. Kinase assays were set up and performed as follows: 
1) Add 10 μL of 30 μM inhibitor (to a final concentration of 
10 μM) or 3% DMSO to a well, 2) Add 10 μL of the appropri-
ate kinase dilution, 3) incubate 20 min  at 20°c, 4) add 10 μL of 
30 μM AtP with 10 μg of poly(Glu4-tyr), 5) incubate 90 min 
at  30°c,  6) add 10 μL of the Kinase-Glo reagent and measure 
the luminescence .
RESuLTS AND DISCuSSION
to generate the protein tyrosine kinase panel for the screen-
ing of the chemical collection, 16 PtKs from five families of 
both receptor and cytoplasmic PtKs were selected (table 
1). For the receptor and certain cytoplasmic PtKs, protein 
fragments containing kinase domains were used, instead of 
full-length proteins, as they are believed to be a good func-
tional model for the search and study of kinase inhibitors 
[11].  expression of the recombinant proteins was carried out 
in the baculovirus expression system, which is believed to 
be optimal for obtaining functionally active PtKs [10]. n-
terminal 6xHis-tags were added to the kinases that allowed 
one-step purification of the His-tagged PtKs from infected 
insect cells using metal chelate affinity chromatography on 
ni2+-sepharose. Protein purification was conducted following 
instructions appropriate for this type of chromatography and 
according to the results of the analytical experiments on the 
optimization of purification conditions. the final protocol is 
presented in the Material and Methods section. 
Purified proteins were analyzed by SDS-PAAGe in de-
naturing conditions, followed by coomassie G-250 staining 
(Fig. 1). All proteins showed good correlation of their electro-
phoretic mobilities with calculated molecular weights, and 
the purities of isolated kinases were at least 70% (table 2).   
the identities of all sixteen recombinant 6xHis-PtKs were 
further confirmed by MALDI-tOF mass spectrometry. the 
amounts of purified proteins were determined using a Brad-
ford protein assay, and the yields of purified kinases from 1 L 
of infected insect cells were 1 to 20 mg (table 2).
the activities of the isolated PtKs were assessed by direct 
one-step measurement of the amount of AtP in the kinase 
assay using a luminescent Kinase-Glo reagent, the method 
having good compatibility with high throughput screening 
[12]. relative luminescence units measured in the kinase as-
say or control reaction were converted to AtP molarities 
in the reaction mixture using the standard curve from the 
AtP titration experiment, then the amounts of AtP (pmoles) 
Table 2. A summary of the 6xHis-PTKs in typical expression and purifica-
tion experiment 
6xHis-PtK MW1
(kDa)
Purity2   
(%)
Yield3  
(mg)
Specific  
activity 4, 
(nmoles/min 
× mg)
Kinase amount 
used in one 
assay5, ng/
assay
Abl 72.5 85 6 118 50
Alk 38.8 75 1 60 90
Blk 63.8 80 3.5 91 60
cSF1r 54.0 80 5 98 60
csk 56.7 90 20 153 40
eph A2 53.4 95 10 110 50
FGFr1 52.5 70 1.5 223 20
FGFr2 53.8 70 1.5 245 20
IGFr1 39.8 80 2 147 40
Insr 51.4 85 6.5 131 40
Kit 55.0 75 3 80 70
Lyn 63.4 75 1.5 332 20
PDGFr-a 67.4 70 2.5 84 70
Pyk2 52.0 80 3.5 86 70
Syk 78 70 1,9 131 50
Yes 65.7 70 1,5 273 20
1 – Calculated molecular weights of the recombinant 6xHis-PTKs. 
2 – The purities of the 6xHis-PTKs were determined by Coumassie 
G-250 staining of SDS-PAAG. 
3 – The yields of purified 6xHis-PTKs from 1 L culture of insect cells 
(10 g) were calculated on the basis of the protein concentration deter-
mined by Bradford assay.
4 – Specific activities were determined by luminescent kinase assay at a 
final protein concentration of 1.5μg/ml (Fig. 2). 
5- The amounts of 6xHis-PTKs hydrolyzing at maximum 80% of the 
initial amount of ATP in 90 min of incubation time were calculated on a 
basis of specific activities and verified experimentally.
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Fig. 1. Analysis of purified samples of recombinant 6xHis-PTKs. The 10 µL 
of protein stocks were loaded onto 10 % SDS–PAAG and the gel was 
stained with Coomassie G-250reSeArcH ArtIcLeS
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hydrolyzed by each kinase in a minute were calculated and 
plotted versus the amount of the kinase  (Fig. 2). the specific 
activities of the recombinant enzymes were determined at a 
final protein concentration of 1.5μg/ml (45 ng per assay) as 
nmoles of the phosphate transferred from AtP to the sub-
strate per min per mg of kinase in standard conditions. the 
specific activities of the PtKs and the amounts to be added to 
the kinase reactions for the screening of the chemical collec-
tion were calculated on the basis of kinase specific activities 
and summarized in table 2. 
the protocol of the screening experiment is presented in 
the Material and Methods section. Potential inhibitors were 
tested simultaneously against each of the 16 target kinases 
in a single working concentration of 10 μM.  the screening 
protocol was designed taking into account the fact that the 
Kinase-Glo reagent provides the linearity of the luminescent 
signal to the AtP amount in an AtP concentration range of 1 
to 100 μM. Based on the AtP starting concentration of 10 μM, 
the amount of kinase in each assay was set so that the enzyme 
could not convert more than 80% of AtP.  the parameter was 
chosen on the basis of the specific activity of the PtK and 
verified in an analytical experiment. After the development 
of the kinase reaction and measurement of the luminescence, 
the relative luciferase units (assay outcome data) were nor-
malized to the controls and presented as percentages of inhi-
bition. the validity of the screening results was confirmed by 
calculating Z′ factor values for each plate using the method of 
Zhang et al. [13]. the Z’ values for most plates were >0.5, and 
the average Z′ value of the entire screen was 0.59±0.1. com-
pounds capable of inhibiting kinase activity by at least 50% 
at 10 μM concentration were chosen for further validation in 
two independent experiments.
Six small molecule inhibitors of the PtKs comprising 
2-hydroxypheno lgroup were found in the screening experi-
ment (Fig. 3). Database search using the chemical Abstracts 
Service (http://www.cas.org/expertise/cascontent/registry/
index.html) and Pubchem BioAssay (http://www.ncbi.nlm.
nih.gov/sites/entrez?db=pcassay) showed that compounds 
I-VI  have not been yet described as kinase inhibitors.  these 
compounds were active against 4 to 9 panel PtKs .  FGFr1, 
Abl, Blk, FGFr2 and PDGFr-a, as well as Lyn, eph A2 and 
csk, were the most frequent targets, while IGFr1, Pyk2, and 
Yes were rarely inhibited. Since all compounds comprised 
the 2-hydroxyphenol group, this led us to suggest that this 
group is precisely the one responsible for the inhibitors’ bind-
ing with the kinase domains. It is known that typical kinase 
inhibitors have pharmacophore (a minimal  core structure 
that is responsible for the biological activity) in which the 
neighbor aromatic amino group and aromatic nitrogen or 
carbonyl oxygen form a couple of correlated hydrogen bonds 
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Fig. 2.  Activities of 6xHis-PTKs. The activities were measured by lumi-
nescent kinase assay and plotted as pmoles of phosphate transferred 
from ATP to the poly (Gly4-Tyr) substrate per min versus increasing 
amounts of the kinases. The averages of the results of two independent 
experiments performed in triplicates are presented
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Fig. 3. The small molecule tyrosine kinase 
inhibitors that were found by screening of the 
chemical collection.  The 2-hydroxyphenol 
group is in the center. The PTKs inhibited by 
each compound at least by 50% are shown88 | ActA nAturAe |  № 3 2009
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with the kinase domain hinge region, mimicking the hydro-
gen bonds formed between this region and the AtP mole-
cule [14]. Molecular docking of the compounds I-VI to csk, 
FGFr1, and FGFr2 having a lot of PDB structures available 
for modeling, which was performed using the Lead Finder 
software [15], revealed that the 2-hydroxyphenol moiety 
was also capable of forming a pair of hydrogen bonds with 
the kinase hinge regions and, thus, that the 2-hydroxyphe-
nol group could be considered as a novel pharmacophore for 
tyrosine kinase inhibitors. Analysis of the Protein Data Bank 
(http://www.pdb.org/) for analogous patterns of kinase in-
hibition revealed that similar hydrogen bonds were formed 
in complexes of phosphoinositide 3-kinase with the flavo-
noids  quercetin and myricetin. It should be noted that the 
molecular weights of the compounds I-VI are significantly 
lower than the MW of known PtK inhibitors, which probably 
explains their ability to dock to the AtP-binding pockets of 
various kinases. At the same time,  the low MW of the com-
pounds specifically provide the possibility of their further 
modification and combinations with the fragments of known 
inhibitors to increase selectivity and efficiency towards the 
selected PtK. In the future, we are planning to verify the 
modeling results by the crystallization and X-ray analysis of 
the PtKs, in complex with the inhibitors.
CONCLuSIONS
We have reported here on the generation of a protein panel 
of the functionally active protein tyrosine kinases and the 
screening of the chemical collection of small molecules that 
allowed to identify six earlier unknown inhibitors comprising 
the 2-hydroxyphenol group. Molecular docking performed 
using the Lead Finder software revealed that the 2-hydroxy-
phenol scaffold could serve as a basis for the design of novel 
PtK inhibitors.  
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